Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors

NCT02637557 is registered in ClinicalTrials.gov with Ironwood Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02637557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02637557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2016
Completion date
April 26, 2017
Enrollment
282 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease